Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA

CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases

LG Chem initiates phase 2 clinical trials in patients with defects in MC4R pathway causing obesity and hyperphagia

LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.

Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery

Three block copolymers added to RESOMER portfolio of bioabsorbable polymers

Cambrex completes US$38 million capacity expansion in High Point, North Carolina

Celanese inks agreement with the Population Council to supply its VitalDose drug delivery platform

The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades

AI to transform all processes in drug development by 2026, predicts CPHI Report

In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs

Gufic Biosciences receives TGA Australia and ANVISA Brazil approval for Parecoxib 40mg injection

Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management

Sanofi announces changes to its Executive Committee

Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.

Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders

In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers

BASF, Promega and Swiss TPH collaborate to drive research for malaria control

Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control